Can Cimzia (certolizumab pegol) be used for spondyloarthritis?
Yes. Cimzia (certolizumab pegol) is used to treat certain types of spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis, where patients have active disease despite standard therapy.
Which kinds of spondyloarthritis does Cimzia cover?
Cimzia is indicated for axial spondyloarthritis conditions such as:
- Ankylosing spondylitis (AS)
- Non-radiographic axial spondyloarthritis (nr-axSpA) in appropriate patients with objective signs of inflammation
When do doctors consider Cimzia instead of other treatments?
Cimzia is typically considered when:
- Disease remains active despite non-biologic treatments (for example, NSAIDs), and/or
- Symptoms are persistent and inflammatory features are present
How is Cimzia taken for spondyloarthritis?
Cimzia is given by injection (subcutaneous). Dosing schedules can differ based on the specific indication and treatment phase, so the exact regimen depends on the prescribing information and the clinician’s plan.
What do patients usually ask about safety for spondyloarthritis?
Common concerns with TNF inhibitors like Cimzia include infection risk and screening requirements before starting therapy. Patients are also typically monitored for signs of infection and other adverse effects during treatment.
Where to check the latest labeling and evidence
For up-to-date information on approvals and related documentation, DrugPatentWatch.com is a useful reference point: DrugPatentWatch – Cimzia (certolizumab pegol)
Sources